Dot pattern background
Logo 20graphic150

INDIGO Biosciences, Inc.

The Nuclear Receptor Experts

  • Stage $1M in TTM Revenue
  • Industry Biotechnology
  • Location State College, PA, US
  • Currency USD
  • Founded February 2005
  • Employees 14
  • Incorporation Type C-corp
  • Website indigobiosciences.com

Company Summary

INDIGO is a low risk investment. Its proven technology and "A" list customers are the basis for the Company's growth and profitability. With the world's largest portfolio of nuclear receptor assay kits and screening services, our product are distributed worldwide. Customers purchase INDIGO products to improve the speed, accuracy, ease, and cost efficiency of their drug discovery research. BFTP and LSGPA are seed stage investors in INDIGO.

Team

  • A11d7b36 d80b 47e5 a7ad 8861df3f34cd
    President and CEO

    A successful entrepreneur with more than 25 years of executive management and engineering experience. His career has spanned multiple industries, technologies, and organization stages. Fred's expertise ranges from being the founding executive of several companies to senior management of a Fortune 1000 business. For the past 10 years, he has focused on evaluating and funding of early stage life science companies.

  • Bob brings with him over 30 yrs of accounting, financial management, and treasury experience with both public and private companies. Bob is also Managing Director and CFO for a private equity firm located in State College. The majority of Bob’s career was with Sunrise Medical Inc., where he held financial management positions over a 17 year period including Global Corporate Controller and Chief Financial Officer of European Operations.

  • Dr. Vanden Heuvel is a recognized expert in the field of nuclear receptor biology and toxicology with over 100 peer-reviewed publications. In addition to his role as CSO at INDIGO, Dr. Vanden Heuvel is a Professor at Penn State University where he is Program Coordinator of the undergraduate Toxicology Program, Co-Director of the Center of Excellence in Nutrigenomics, and leads an extramurally funded research program.

  • Dr. Sherf joined the Company in 2008. He has worked in the biotechnology industry since 1994, has particular expertise in cell-based reporter assay design and optimization, product development, and high-throughput screening applications for drug discovery. As CTO, he oversees INDIGO Biosciences’ product development, manufacturing, and technology transfer initiatives, as well as directing all contract service related activities.

Advisors

Previous Investors